JanOne Shares Jumped After the Issuance of U.S. Patent Covering a Method of Improving Nerve Function Using JAN101
Jun 7, 2022 By MarketDepth
JanOne Inc. (NASDAQ: JAN) shares spike more than 50% on Tuesday after the company announced that a patent was issued that covers a method of improving nerve function using JAN101. JAN101 (formerly known as TV1001SR), is a potential treatment for peripheral artery disease (PAD), a vascular disease that affects more than 8.5 million people in the U.S. and more than 60 million people worldwide.
“This patent further protects JanOne Inc.’s product for use in treating PAD by extending the use of JAN101 to treat the nerve damage caused by microvascular disease. Microvascular disease is a major problem for PAD patients: it leads to restricted blood flow in the affected limb, which in turn leads to nerve damage and severe pain. Recent studies have in fact suggested that PAD is a microvascular disease, so the observation that JAN101 improves microvascular and nerve function is crucial in treating this disease.”Dr. Tony Giordano, JanOne Inc.’s Chief Scientific Officer
Dr. Amol Soin, a leading pain physician and JanOne’s Chief Medical Officer, added, “We believe that nerve damage plays a major role in promoting pain and thus studied whether JAN101 could improve nerve sensory velocity and nerve sensory conductance in a previous trial I oversaw. Our previous studies showed that JAN101 improved nerve conduction velocity, which leads us to believe that it may not only improve pain but could also improve nerve function.”
JanOne Licensed to Use Patent
This method for treating pain was co-discovered by Dr. Christopher Kevil, Vice Chancellor for Research and Dean of the School of Graduate Studies at LSU Health Shreveport. This newly approved patent is owned by LSU Health Shreveport and is exclusively licensed to JanOne Inc. It is the latest United States patent to be issued in connection with JanOne’s Inc.’s PAD and pain development program.